BIOASTER is an independent institute dedicated to infectious diseases and microbiology. With eight funding members: Lyonbiopole and the Institut Pasteur, three major industrial companies - Sanofi, Institut Mérieux, Danone Research - and three academic research centers - INSERM,CNRS, and CEA - as well as a group comprising 40 SMBs (small- and medium-sized businesses) from the Rhône-Alpes and Paris areas. BIOASTER was established as a foundation for scientific cooperation based on an innovative public/private partnership model. It offers a novel approach to R&D based on integrating several scientific and technological disciplines. BIOASTER conducts independent and collaborative interdisciplinary R&D activities on the frontier between basic and industrial development to ensure optimal alignment between research and innovation in the fields of infectious diseases and microbiology and expand our understanding of intestinal microbiota and its impact on health.
The European Vaccine Initiative (EVI) is leading European efforts to develop effective, accessible, and affordable vaccines against diseases of poverty. EVI’s vision is 'a world free of the intolerable burden of diseases of poverty within the coming decades'. EVI is contributing to the global efforts to control these diseases in three main ways:
Fondation Mérieux was established in 1967 by Docteur Charles Mérieux, in honour of his father Marcel Mérieux, student of Louis Pasteur and founder of the Institut Mérieux in 1897. It was awarded official charitable status in 1976. Fondation Mérieux is an independent family foundation. Each successive generations sharing common values in the Pasteurian tradition, have succeeded in passing on their vision of biology serving public health worldwide. By bringing together partners with a wide range of skills and cultural backgrounds, Dr. Charles Mérieux has succeeded in creating an exceptional international network. Fondation Mérieux has thus played a unifiying role catalyzing initiatives with the common goal of fighting infectious diseases worldwide. It is currently present in a dozen countries and offers a specific model based on a long history of expertise in clinical biology and a comprehensive approach to public health issues. Its mission is to contribute to global health by strengthening local capacities of developing countries to reduce the impact of infectious diseases on vulnerable populations.
Its action is based around four main priorities:
Since its creation, the Foundation gives priority to the opening and partnership initiating and leading a major international scientific network. It plays a catalysing role in both local and international initiatives acting invariably under the same objective of improving public health.
Fondation Mérieux is a funding Partner of the Master LIVE.
Immuno Valley is a business driven public-private consortium of over forty scientific and business partners. Operating at the interface of human and animal health, Immuno Valley is the premier One Health consortium for recognising science and business opportunities and combining R&D expertise in the field of infectious diseases. Immuno Valley monitors trends in research & development and matches scientific findings with business and funding opportunities. The ultimate aim is to translate R&D expertise into new products for the diagnosis, prevention and treatment of infectious diseases.
Consortium partners: Amsterdam Academic Medical Centre, Amsterdam Economic Board, Central Veterinary institute of Wageningen, GD animal health, Intravacc, Research Ant, Sanquin Bloedvoorziening, Task Force Innovation Utrecht, TNO innovation for life, Utrecht University, Utrecht University Medical Center, VU Medical Center, Ardol, BioXpert, Ceva Santé Animale, Crossbeta biosciences, DaaVision, Dechra Veterinary Products, De Stolle Kracht, Dopharma, Eli Lilly Elanco Animal Health, EpiVax, Farma Research Animal Health, Greenvalley International, InnatOss, InnoServ, Merial, Metabolon, Micreos, MSD Animal Health, Nizo, Nutriad, Nytor, OMFL, Perstorp, Prionics, Purac Corbion, Schothorst Feed Research, U-Protein Express BV, Zoetis B.V., Ministry of Economics Affaires Agriculture and innovation, Municipality of Amsterdam-Lelystad-Utrecht, Province of Flevoland-Noord-Holland-Utrecht
The Barcelona Institute for Global Health, ISGlobal, is the fruit of an innovative alliance between academic, government, and philanthropic institutions to contribute to the efforts undertaken by the international community to address the challenges in global health.
ISGlobal provides a hub of excellence in research and health care that will continue and expand the work started by Hospital Clínic and the University of Barcelona. The pivotal mechanism of its work model is the transfer of knowledge generated by scientific research to practice, a task undertaken by the Training and the Policy and Global Development departments.
Its ultimate goal is to help close the gaps in health disparities between and within different regions of the world.
Since 2013, ISGlobal works in alliance with the Centre for Research in Environmental Epidemiology (CREAL) . CREALis working towards promoting and developing advanced epidemiological research into the environmental factors that affect human health, in order to help prevent and control their harmful effects.
Through this mechanism of strategic alliance, ISGlobal has successfully consolidated a cutting-edge cluster of research expertise with capacity to address health challenges, including infectious diseases and non-communicable chronic diseases, with a strong focus on their environmental determinants.
Accredited as a world competitive cluster by the French State on July 12 th, 2005, Lyonbiopole focuses on the global fight against human and animal infectious diseases and cancers, from diagnostic and prevention to treatment, including innovative delivery systems. Lyon biopole, a world competitiveness cluster, focuses on the fight against human and animal infectious diseases and cancers.
The Pirbright Institute provides the UK with capacity to predict, detect, understand and respond to the threat and potential attack of serious viral diseases of livestock and viruses that spread from animals to humans. These viral diseases may not be present in the UK (endemic) and only circulating abroad (exotic). The Institute's strategic priorities are to:
The Network for Education and Support in Immunisation (NESI) was officially launched on 1 September 2002.
NESI was built on the experience of the International Network for Eastern and Southern Africa on Hepatitis B Vaccination, which was established in 1999 and included five universities in Eastern and Southern Africa (Kenya, Tanzania, Zambia, Zimbabwe and South Africa), Ministries of Health in Africa and the University of Antwerp. The purpose of this network was to translate research on hepatitis B through capacity building and advocacy into universal access to hepatitis B vaccination in the partner countries.
With the development of new vaccines and increased commitment by development partners and private sector initiatives to strengthen vaccine supply and immunisation services, there are more opportunities to prevent more diseases in more children. This led to the establishment of NESI, which is a collaborative network focusing on capacity building for the strengthening of existing immunisation systems and introduction of new vaccines, with a broad technical scope and wide geographical focus.
I-REIVAC is the French clinical network dedicated to vaccinology . It was created in 2008 by four clinical research centers (CIC), founding members. It currently includes 17 structures for clinical research. I-REIVAC promotes clinical research in vaccinology, the emergence of translational research (or exploratory) through interactions between academic researchers, clinicians and industry, the France attractiveness for vaccine trials, particularly for early phase studies (I and II). The I-REIVAC main goals are to sustain the "proof of concept" studies, increase the numbers of clinical trials in vaccinology in France and in the European Community, recruit the research participants to be effective, harmonize procedures and tools for administrative and financial management within the quality approach and establish a biobank available to partners.
Vaccines Europe, formerly European Vaccine Manufacturers (EVM), is the specialised vaccines group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), the professional association of the pharmaceutical industry in Europe.
Formed in 1991, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe which account for a large share of human vaccines used worldwide. Companies represented within Vaccines Europe are involved in research and development (R&D), clinical trials, production and marketing of vaccines and are dedicated to improving public health through immunisation.
Vaccines Europe aims to:
Vaccines Europe members: Abbott Biologicals, Crucell, GlaxoSmithKline Vaccines, ImmBio, MedImmune, MSD, Novartis Vaccines, Pfizer Vaccines, Sanofi Pasteur, Sanofi Pasteur MSD, Takeda, Vaxeal
Adjuvants are increasingly used by the vaccine research and development community, particularly for their ability to enhance immune responses and for their dose-sparing properties. However, they are not readily available to the majority of public sector vaccine research groups, and even those with access to suitable adjuvants may still fail in the development of their vaccines because of lack of knowledge on how to correctly formulate the adjuvants. This shortcoming led the World Health Organization to promote the establishment of the Vaccine Formulation Laboratory (VFL) at the University of Lausanne, in January 2010. The VFL acts as a platform for adjuvants with the following main strategies: Supply of adjuvants for research and preclinical development; custom vaccine formulation services; transfer of technology to vaccine manufacturers; and training on adjuvants and vaccine formulation.
Vaccine Formulation Institute (VFI), established in 2012, operates as a not-for-profit (limited by guarantee) company registered under the laws of England. Its mission is to provide open access to education, training, adjuvants, and formulation technology. VFI synergises and catalyses the various activities of the Lausanne platform on adjuvant and formulation by providing project coordination, management, consultancy, trainings and contract management to activities linked with formulation of adjuvanted vaccines.
WHO is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends. In the 21st century, health is a shared responsibility, involving equitable access to essential care and collective defence against transnational threats.